Gait and Equilibrium in Subcortical Vascular Dementia

Table 3

A synopsis of the SNC drugs employed by the patients.

Drug utilization	baseline	12 months	24 months	36 months
Benzodiazepines	44 patients	89 patients	98 patients	104 patients
lorazepam, mean (±SD) dose	1.27± 0.3 mg/day	2.56 ± 0.65 mg/day	3.94 ± 1.5 mg/day	4.56 ± 1.65 mg/day
delorazepam, mean (±SD) dose	1.21 ± 0.8 mg/day	2.61 ± 1.29 mg/day	3.1 ± 1.54 mg/day	4.1 ± 1.89 mg/day
bromazepam, mean (±SD) dose	2.11 ± 1.1 mg/day	3.41 ± 0.8 mg/day	4.6 ± 1.4 mg/day	5.41 ± 1.8 mg/day
Typical neuropletics	28 patients	56 patients	98 patients	167 patients
Haloperidol, mean (±SD) dose	1.56 ± 0.54 mg/day	2.34 ± 0.67 mg/day	2.87 ± 1.54 mg/day	3.56 ± 0.54 mg/day
promazine chloridate, mean (±SD) dose	53.12 ± 12.23 mg/day	59.12 ± 16. 91 mg/day	63.12 ± 7.2 mg/day	67.12 ± 1.56 mg/day
Atypical neurolpetics	4 patients	23 patients	63 patients	53 patients
olanzapine, mean (±SD) dose	4.0 ± 1.10 mg/day	5.1 ± 2.34 mg/day	5.6 ± 1.6 mg/day	5.9 ± 2.94 mg/day
quetiapine, mean (±SD) dose	37.5 ± 5.21 mg/day	56.9 ± 3.5 mg/day	66.8 ± 3.5 mg/day	89.9 ± 3.5 mg/day